Lipum merges with Flerie and the merger is completed
The Companies Registration Office has registered the merger. Lipum's assets are transferred to Flerie, which retains the name and seat in Stockholm.
See the latest news and media coverage for Lipum. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biopharmaceutical company developing anti-inflammatory drugs
lipum.seLast updated
In short: Lipum was absorbed by Flerie AB through a merger, finalized in March 2026, which followed a significant €8 million grant for Phase 2 clinical trials.
The Companies Registration Office has registered the merger. Lipum's assets are transferred to Flerie, which retains the name and seat in Stockholm.
The merger is registered on 20 March 2026. Lipum is dissolved and delisted on 18 March 2026. Shareholders receive Flerie shares as consideration.
The consortium receives 8 million euros for clinical phase 2 study of SOL-116 against rheumatoid arthritis. The funding supports development without ownership dilution.
The team focuses entirely on the study to demonstrate clinical evidence.
The merger between investment firm Flerie and pharmaceutical company Lipum has now been finalized, according to a press release.Under the terms of the transaction, Lipum...
Redeye ceases its coverage of Lipum and will not provide research on the company following the completion of the merger between Flerie and Lipum and...
The Swedish Companies Registration Office (Sw. Bolagsverket) has granted permission to Flerie AB (publ) (“Flerie”) to carry out the merger plan concerning the merger between...
A signed agreement with the European Commission would mean a significant capital injection without any dilution of ownership. Lipum leads a European consortium consisting of...
Track Lipum and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Lipum and other trending companies.